Maximum Dosage for Dayvigo (Lemborexant)
The maximum recommended dose of Dayvigo (lemborexant) is 10 mg taken once nightly, immediately before bed with at least 7 hours remaining before planned awakening. 1
Standard Dosing
- The starting dose is 5 mg once nightly, which may be increased to the maximum of 10 mg based on clinical response and tolerability. 1
- The medication should be taken no more than once per night, immediately before going to bed. 1
- At least 7 hours must remain before the planned time of awakening to minimize next-day impairment. 1
- Taking lemborexant with or soon after a meal may delay sleep onset. 1
Dose Reductions Required in Specific Situations
With CYP3A Inhibitors
- Weak CYP3A inhibitors (e.g., fluoxetine, ranitidine): Maximum dose is 5 mg once nightly. 1, 2
- Moderate or strong CYP3A inhibitors (e.g., erythromycin, verapamil, itraconazole, fluconazole): Avoid concomitant use entirely. 1, 2
With Hepatic Impairment
- Moderate hepatic impairment: Maximum dose is 5 mg once nightly. 1
- Severe hepatic impairment: Lemborexant is not recommended. 1
Clinical Efficacy Evidence
- Both the 5 mg and 10 mg doses demonstrated statistically significant improvements in sleep onset latency, wake after sleep onset, and sleep efficiency compared to placebo in phase 3 trials. 3
- A 2025 meta-analysis of 1976 patients found no significant difference in efficacy between 5 mg and 10 mg doses, though somnolence was more common with higher doses. 4
- The 5 mg dose may be preferable for patients at risk of excessive daytime somnolence while maintaining therapeutic benefit. 4
Safety Considerations
- The plasma concentration at 9 hours post-dose is approximately 27% of maximum concentration with the 10 mg dose, with a mean effective half-life of 17-19 hours. 5
- Driving impairment was observed in some subjects taking 10 mg, particularly when less than a full night's sleep remained. 1
- Treatment-emergent adverse events and somnolence are dose-dependent, occurring more frequently at 10 mg versus 5 mg. 4
- Lemborexant was well tolerated in postmarketing surveillance with 7.65% experiencing somnolence and low rates of parasomnias (nightmares 1.76%, abnormal dreams 0.59%, sleep paralysis 0.20%). 6
Key Pitfalls to Avoid
- Never exceed 10 mg in any patient population, as higher doses provide no additional efficacy and increase adverse effects. 2, 4
- Do not combine with moderate or strong CYP3A inhibitors or inducers, as this significantly alters drug exposure. 1
- Avoid alcohol and other CNS depressants due to additive effects that increase fall risk, especially in elderly patients. 1
- Do not use with less than 7 hours of remaining sleep time, as this substantially increases next-day impairment risk. 1